Litcius/Paper detail

Remodeling the tumor immune microenvironment through hydrogel encapsulated G-Rh2 in situ vaccine and systemic immunotherapy

Chunhua Li, Dan Lei, Yudong Huang, Yuanhao Jing, Wanru Wang, Lanqi Cen, Zijian Wei, Anni Chen, Xiaoyu Feng, Yushu Wang, Lixia Yu, Ying Chen, Rutian Li

2024Materials Today Bio11 citationsDOIOpen Access PDF

Abstract

Ginsenoside Rh2 (G-Rh2) is a vital bioactive compound in Traditional Chinese Medicine, celebrated for its strong pharmacological properties, particularly its potent antitumor effects. However, its poor water solubility and limited bioavailability have necessitated the development of a novel drug delivery method. In this study, we utilized an indocyanine green carboxylic acid-hydroxypropyl cellulose-abietic acid-bovine serum albumin hydrogel (ICG-HPC-AA/BSA hydrogel) as a tumor in situ vaccine to enhance the permeability, retention, and tumor-targeted therapeutic efficacy of G-Rh2. We examined the therapeutic impact of a G-Rh2-loaded hydrogel combined with systemic PD-1 antibody treatment in murine models of H22 liver cancer and CT26 colon cancer. Additionally, we explored the immune microenvironment of the tumors influenced by this in situ vaccination strategy.

Topics & Concepts

ImmunotherapyTumor microenvironmentImmune systemImmunologyIn situMedicineChemistryOrganic chemistryImmunotherapy and Immune ResponsesNanoplatforms for cancer theranosticsImmune cells in cancer